SWK Holdings Corp (SWKH)
15.80
-0.67
(-4.07%)
USD |
NASDAQ |
Dec 20, 16:00
15.91
+0.11
(+0.70%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 193.28M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -10.46% |
Valuation | |
PE Ratio | 16.99 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 4.529 |
Price to Book Value | 0.6819 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.1102 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 83.76% |
Profile
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment. |
URL | https://www.swkhold.com |
Investor Relations URL | N/A |
HQ State/Province | Texas |
Sector | Financials |
Industry | Financial Services |
Equity Style | Small Cap/Value |
Next Earnings Release | Mar. 21, 2025 (est.) |
Last Earnings Release | Nov. 14, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment. |
URL | https://www.swkhold.com |
Investor Relations URL | N/A |
HQ State/Province | Texas |
Sector | Financials |
Industry | Financial Services |
Equity Style | Small Cap/Value |
Next Earnings Release | Mar. 21, 2025 (est.) |
Last Earnings Release | Nov. 14, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |